格拉提拉默酸盐可以通过调节多发性硬化症患者的氧化应激来预防认知障碍吗?
Anna Gil-Sánchez1, Hugo Gonzalo1, Marc Canudes1
1Institut de Recerca Biomèdica de Lleida (IRBLleida), 25198 Lleida, Spain.
Pharmaceuticals (Basel, Switzerland)
|April 27, 2024
概括
在多发性硬化症患者中,格拉提拉默酸盐没有改善认知或氧化应激. 乳酸盐水平升高可能表明MS的一些患者的认知功能保持.
科学领域:
- 神经免疫学 神经免疫学
- 神经科学是一个神经科学.
- 生物化学 生物化学
背景情况:
- 多发性硬化症 (MS) 是一种自身免疫性疾病,导致脱髓化和神经炎症,经常导致认知障碍.
- 认知能力下降是MS (pwMS) 患者面临的重大挑战.
研究的目的:
- 通过调节氧化应激 (OS) 来评估glatiramer乙酸 (GA) 在预防pwMS认知衰退方面的有效性.
- 为了比较pwMS和对照对象 (CS) 之间的认知表现.
主要方法:
- 一项前性的,多中心的,横截面的病例控制研究,涉及三个组:GA治疗的pwMS,未治疗的pwMS和CS (1:1:1比).
- 对参与者进行了神经心理测试和血液采样,扩大残疾状况尺度≤3.0和≥5年的MS.
- 分析包括认知功能,氧化应激标志物和乳酸盐水平.
主要成果:
- CS表现出比pwMS显著更好的认知表现 (p < 0.0001).
- 在GA治疗和未治疗的pWMS之间,没有发现认知或氧化方面的显著差异.
- 与认知受损的pwMS相比,在认知保持的pwMS中观察到乳酸盐水平升高 (p = 0.038).
结论:
- 与CS相比,PwMS的认知表现较差.
- 在这个队列中,格拉提拉乙酸没有显示出对认知或氧化应激的显著益处.
- 乳酸酸可以作为一种潜在的生物标志物,用于MS患者的认知保存.
更多相关视频
05:55Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
Published on: December 1, 2023
814
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
121
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
121
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
